{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:54:05Z","timestamp":1774972445421,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"48","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI20\/00275"],"award-info":[{"award-number":["FI20\/00275"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PT17\/0009\/0019"],"award-info":[{"award-number":["PT17\/0009\/0019"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PhD fellowship from the National Secretary for Higher Education, Science, Technology and Innovation of Ecuador"},{"name":"Co-funded by FEDER"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,12,2]]},"DOI":"10.1038\/s41388-021-02049-0","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T18:03:31Z","timestamp":1633629811000},"page":"6614-6626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor"],"prefix":"10.1038","volume":"40","author":[{"given":"Alfonso","family":"Garc\u00eda-Valverde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3877-4170","authenticated-orcid":false,"given":"Sergi","family":"Sayols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"G\u00f3mez-Peregrina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3640-0498","authenticated-orcid":false,"given":"Daniel F.","family":"Pilco-Janeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"Olivares-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"de \u00c1lava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Maurel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rubi\u00f3-Casadevall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Gut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Barretina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Carles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George D.","family":"Demetri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-0664","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1416-8739","authenticated-orcid":false,"given":"C\u00e9sar","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"2049_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2010.0116","volume":"8","author":"GD Demetri","year":"2010","unstructured":"Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw. 2010;8:S1\u201341.","journal-title":"J Natl Compr Cancer Netw"},{"key":"2049_CR2","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-20-1706","volume":"26","author":"C Serrano","year":"2020","unstructured":"Serrano C, George S. Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin Cancer Res. 2020;26:5078\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1706","journal-title":"Clin Cancer Res"},{"key":"2049_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrc3087","volume":"11","author":"BS Taylor","year":"2011","unstructured":"Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011;11:541\u201357. https:\/\/doi.org\/10.1038\/nrc3087","journal-title":"Nat Rev Cancer"},{"key":"2049_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ng.2974","volume":"46","author":"Y Wang","year":"2014","unstructured":"Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, et al. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014;46:601\u20136. https:\/\/doi.org\/10.1038\/ng.2974","journal-title":"Nat Genet"},{"key":"2049_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577\u201380.","journal-title":"Science"},{"key":"2049_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708\u201310. https:\/\/doi.org\/10.1126\/science.1079666","journal-title":"Science"},{"key":"2049_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl J Med. 2002;347:472\u201380. https:\/\/doi.org\/10.1056\/NEJMoa020461","journal-title":"N. Engl J Med"},{"key":"2049_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/path.2382","volume":"216","author":"B Liegl","year":"2008","unstructured":"Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64\u201374. https:\/\/doi.org\/10.1002\/path.2382","journal-title":"J Pathol"},{"key":"2049_CR9","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41416-019-0389-6","volume":"120","author":"C Serrano","year":"2019","unstructured":"Serrano C, Marino-Enriquez A, Tao DL, Ketzer J, Eilers G, Zhu M, et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J cancer. 2019;120:612\u201320. https:\/\/doi.org\/10.1038\/s41416-019-0389-6","journal-title":"Br J cancer"},{"key":"2049_CR10","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","volume":"24","author":"MC Heinrich","year":"2006","unstructured":"Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24:4764\u201374. https:\/\/doi.org\/10.1200\/JCO.2006.06.2265","journal-title":"J Clin Oncol"},{"key":"2049_CR11","doi-asserted-by":"publisher","first-page":"9015","DOI":"10.1158\/0008-5472.CAN-08-1935","volume":"68","author":"Y Liu","year":"2008","unstructured":"Liu Y, Perdreau SA, Chatterjee P, Wang L, Kuan SF, Duensing A. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis. Cancer Res. 2008;68:9015\u201323. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1935","journal-title":"Cancer Res"},{"key":"2049_CR12","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/0008-5472.CAN-13-0579","volume":"73","author":"S Boichuk","year":"2013","unstructured":"Boichuk S, Parry JA, Makielski KR, Litovchick L, Baron JL, Zewe JP, et al. The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis. Cancer Res. 2013;73:5120\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0579","journal-title":"Cancer Res"},{"key":"2049_CR13","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1158\/0008-5472.CAN-14-2564","volume":"75","author":"NA Cohen","year":"2015","unstructured":"Cohen NA, Zeng S, Seifert AM, Kim TS, Sorenson EC, Greer JB, et al. Pharmacological inhibition of KIT activates MET signaling in gastrointestinal stromal tumors. Cancer Res. 2015;75:2061\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2564","journal-title":"Cancer Res"},{"key":"2049_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1158\/2159-8290.CD-14-0763","volume":"5","author":"F Li","year":"2015","unstructured":"Li F, Huynh H, Li X, Ruddy DA, Wang Y, Ong R, et al. FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors. Cancer Discov. 2015;5:438\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0763","journal-title":"Cancer Discov"},{"key":"2049_CR15","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1038\/sj.onc.1207525","volume":"23","author":"A Duensing","year":"2004","unstructured":"Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004;23:3999\u20134006. https:\/\/doi.org\/10.1038\/sj.onc.1207525","journal-title":"Oncogene"},{"key":"2049_CR16","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1038\/sj.onc.1210558","volume":"26","author":"S Bauer","year":"2007","unstructured":"Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase\/AKT is a crucial survival pathway. Oncogene. 2007;26:7560\u20138. https:\/\/doi.org\/10.1038\/sj.onc.1210558","journal-title":"Oncogene"},{"key":"2049_CR17","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1038\/sj.onc.1210464","volume":"26","author":"MJ Zhu","year":"2007","unstructured":"Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD, Fletcher JA. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene. 2007;26:6386\u201395. https:\/\/doi.org\/10.1038\/sj.onc.1210464","journal-title":"Oncogene"},{"key":"2049_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nature09409","volume":"467","author":"P Chi","year":"2010","unstructured":"Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010;467:849\u201353. https:\/\/doi.org\/10.1038\/nature09409","journal-title":"Nature"},{"key":"2049_CR19","doi-asserted-by":"publisher","first-page":"E8448","DOI":"10.1073\/pnas.1711449114","volume":"114","author":"B Bosbach","year":"2017","unstructured":"Bosbach B, Rossi F, Yozgat Y, Loo J, Zhang JQ, Berrozpe G, et al. Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor. Proc Natl Acad Sci USA. 2017;114:E8448\u2013E57. https:\/\/doi.org\/10.1073\/pnas.1711449114","journal-title":"Proc Natl Acad Sci USA"},{"key":"2049_CR20","doi-asserted-by":"publisher","first-page":"14440","DOI":"10.1073\/pnas.251541198","volume":"98","author":"MD Gomes","year":"2001","unstructured":"Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA. 2001;98:14440\u20135. https:\/\/doi.org\/10.1073\/pnas.251541198","journal-title":"Proc Natl Acad Sci USA"},{"key":"2049_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/s0092-8674(04)00400-3","volume":"117","author":"M Sandri","year":"2004","unstructured":"Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117:399\u2013412. https:\/\/doi.org\/10.1016\/s0092-8674(04)00400-3","journal-title":"Cell"},{"key":"2049_CR22","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1634\/theoncologist.2019-0297","volume":"25","author":"A Bardia","year":"2020","unstructured":"Bardia A, Gounder M, Rodon J, Janku F, Lolkema MP, Stephenson JJ, et al. Phase Ib study of combination therapy with MEK inhibitor binimetinib and phosphatidylinositol 3-kinase inhibitor buparlisib in patients with advanced solid tumors with RAS\/RAF alterations. Oncologist. 2020;25:e160\u2013e9. https:\/\/doi.org\/10.1634\/theoncologist.2019-0297","journal-title":"Oncologist"},{"key":"2049_CR23","first-page":"699","volume":"2","author":"A Frolov","year":"2003","unstructured":"Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther. 2003;2:699\u2013709.","journal-title":"Mol Cancer Ther"},{"key":"2049_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/labinvest.2009.138","volume":"90","author":"JL Chou","year":"2010","unstructured":"Chou JL, Su HY, Chen LY, Liao YP, Hartman-Frey C, Lai YH, et al. Promoter hypermethylation of FBXO32, a novel TGF-beta\/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Investig. 2010;90:414\u201325. https:\/\/doi.org\/10.1038\/labinvest.2009.138","journal-title":"Lab Investig"},{"key":"2049_CR25","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1038\/onc.2013.471","volume":"33","author":"R Ciarapica","year":"2014","unstructured":"Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini PP, et al. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1\/MAFbx). Oncogene. 2014;33:4173\u201384. https:\/\/doi.org\/10.1038\/onc.2013.471","journal-title":"Oncogene"},{"key":"2049_CR26","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1038\/onc.2016.479","volume":"36","author":"H Zhou","year":"2017","unstructured":"Zhou H, Liu Y, Zhu R, Ding F, Wan Y, Li Y, et al. FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation. Oncogene. 2017;36:3312\u201321. https:\/\/doi.org\/10.1038\/onc.2016.479","journal-title":"Oncogene"},{"key":"2049_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nrm2190","volume":"8","author":"A van der Horst","year":"2007","unstructured":"van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol cell Biol. 2007;8:440\u201350. https:\/\/doi.org\/10.1038\/nrm2190","journal-title":"Nat Rev Mol cell Biol"},{"key":"2049_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/ncb1676","volume":"10","author":"JY Yang","year":"2008","unstructured":"Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10:138\u201348. https:\/\/doi.org\/10.1038\/ncb1676","journal-title":"Nat Cell Biol"},{"key":"2049_CR29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/nm.2772","volume":"18","author":"SP Tenbaum","year":"2012","unstructured":"Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, et al. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med. 2012;18:892\u2013901. https:\/\/doi.org\/10.1038\/nm.2772","journal-title":"Nat Med"},{"key":"2049_CR30","doi-asserted-by":"publisher","first-page":"20814","DOI":"10.1074\/jbc.M500528200","volume":"280","author":"C Skurk","year":"2005","unstructured":"Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem. 2005;280:20814\u201323. https:\/\/doi.org\/10.1074\/jbc.M500528200","journal-title":"J Biol Chem"},{"key":"2049_CR31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrm1471","volume":"5","author":"T Cardozo","year":"2004","unstructured":"Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol. 2004;5:739\u201351. https:\/\/doi.org\/10.1038\/nrm1471","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2049_CR32","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1245\/s10434-011-2190-5","volume":"19","author":"D Wang","year":"2012","unstructured":"Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant\/adjuvant imatinib mesylate for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012;19:1074\u201380. https:\/\/doi.org\/10.1245\/s10434-011-2190-5","journal-title":"Ann Surg Oncol"},{"key":"2049_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nm.4474","volume":"24","author":"ML Hyer","year":"2018","unstructured":"Hyer ML, Milhollen MA, Ciavarri J, Fleming P, Traore T, Sappal D, et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med. 2018;24:186\u201393. https:\/\/doi.org\/10.1038\/nm.4474","journal-title":"Nat Med"},{"key":"2049_CR34","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/nature05902","volume":"447","author":"J Jin","year":"2007","unstructured":"Jin J, Li X, Gygi SP, Harper JW. Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature. 2007;447:1135\u20138. https:\/\/doi.org\/10.1038\/nature05902","journal-title":"Nature"},{"key":"2049_CR35","doi-asserted-by":"publisher","first-page":"E5746","DOI":"10.1073\/pnas.1802079115","volume":"115","author":"ML Hemming","year":"2018","unstructured":"Hemming ML, Lawlor MA, Zeid R, Lesluyes T, Fletcher JA, Raut CP, et al. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci USA. 2018;115:E5746\u2013E55. https:\/\/doi.org\/10.1073\/pnas.1802079115","journal-title":"Proc Natl Acad Sci USA"},{"key":"2049_CR36","doi-asserted-by":"publisher","unstructured":"Grunewald S, Klug LR, Muhlenberg T, Lategahn J, Falkenhorst J, Town A, et al. Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain. Cancer Discov. 2020. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0487","DOI":"10.1158\/2159-8290.CD-20-0487"},{"key":"2049_CR37","doi-asserted-by":"publisher","first-page":"7287","DOI":"10.1158\/1078-0432.CCR-19-2150","volume":"25","author":"C Serrano","year":"2019","unstructured":"Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, et al. Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine kinase inhibitor refractory gastrointestinal stromal tumors. Clin Cancer Res. 2019;25:7287\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2150","journal-title":"Clin Cancer Res"},{"key":"2049_CR38","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.15.7461","journal-title":"J Clin Oncol"},{"key":"2049_CR39","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","volume":"22","author":"SO Dolly","year":"2016","unstructured":"Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2016;22:2874\u201384. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2225","journal-title":"Clin Cancer Res"},{"key":"2049_CR40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/2159-8290.CD-17-0468","volume":"8","author":"L Ran","year":"2018","unstructured":"Ran L, Chen Y, Sher J, Wong EWP, Murphy D, Zhang JQ, et al. FOXF1 defines the core-regulatory circuitry in gastrointestinal stromal tumor. Cancer Discov. 2018;8:234\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0468","journal-title":"Cancer Discov"},{"key":"2049_CR41","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1074\/jbc.M411346200","volume":"280","author":"LA Tintignac","year":"2005","unstructured":"Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem. 2005;280:2847\u201356. https:\/\/doi.org\/10.1074\/jbc.M411346200","journal-title":"J Biol Chem"},{"key":"2049_CR42","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/emboj.2008.52","volume":"27","author":"J Lagirand-Cantaloube","year":"2008","unstructured":"Lagirand-Cantaloube J, Offner N, Csibi A, Leibovitch MP, Batonnet-Pichon S, Tintignac LA, et al. The initiation factor eIF3-f is a major target for atrogin1\/MAFbx function in skeletal muscle atrophy. EMBO J. 2008;27:1266\u201376. https:\/\/doi.org\/10.1038\/emboj.2008.52","journal-title":"EMBO J"},{"key":"2049_CR43","doi-asserted-by":"publisher","first-page":"14333","DOI":"10.1073\/pnas.1000248107","volume":"107","author":"A Gupta","year":"2010","unstructured":"Gupta A, Roy S, Lazar AJ, Wang WL, McAuliffe JC, Reynoso D, et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci USA. 2010;107:14333\u20138. https:\/\/doi.org\/10.1073\/pnas.1000248107","journal-title":"Proc Natl Acad Sci USA"},{"key":"2049_CR44","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-19-1069","volume":"19","author":"A Garcia-Valverde","year":"2020","unstructured":"Garcia-Valverde A, Rosell J, Serna G, Valverde C, Carles J, Nuciforo P, et al. Preclinical activity of PI3K inhibitor copanlisib in gastrointestinal stromal tumor. Mol Cancer Ther. 2020;19:1289\u201397. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-1069","journal-title":"Mol Cancer Ther"},{"key":"2049_CR45","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-14-1397","volume":"20","author":"AP Garner","year":"2014","unstructured":"Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014;20:5745\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1397","journal-title":"Clin Cancer Res"},{"key":"2049_CR46","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382. https:\/\/doi.org\/10.1038\/nmeth.2019","journal-title":"Nat Methods"},{"key":"2049_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-016-0050-6","volume":"6","author":"J Maurel","year":"2016","unstructured":"Maurel J, Lopez-Pousa A, Calabuig S, Bague S, Del Muro XG, Sanjuan X, et al. Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. Clin Sarcoma Res. 2016;6:10 https:\/\/doi.org\/10.1186\/s13569-016-0050-6","journal-title":"Clin Sarcoma Res"},{"key":"2049_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05912-z","volume":"9","author":"L Pascual-Reguant","year":"2018","unstructured":"Pascual-Reguant L, Blanco E, Galan S, Le Dily F, Cuartero Y, Serra-Bardenys G, et al. Lamin B1 mapping reveals the existence of dynamic and functional euchromatin lamin B1 domains. Nat Commun. 2018;9:3420 https:\/\/doi.org\/10.1038\/s41467-018-05912-z","journal-title":"Nat Commun"},{"key":"2049_CR49","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1172\/JCI124108","volume":"129","author":"GA Vitiello","year":"2019","unstructured":"Vitiello GA, Bowler TG, Liu M, Medina BD, Zhang JQ, Param NJ, et al. Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor. J Clin Investig. 2019;129:1863\u201377. https:\/\/doi.org\/10.1172\/JCI124108","journal-title":"J Clin Investig"},{"key":"2049_CR50","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47 https:\/\/doi.org\/10.1093\/nar\/gkv007","journal-title":"Nucleic Acids Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-02049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-02049-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-02049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T10:07:40Z","timestamp":1638439660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-02049-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":50,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2021,12,2]]}},"alternative-id":["2049"],"URL":"https:\/\/doi.org\/10.1038\/s41388-021-02049-0","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"22 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS has received consulting fees (advisory role) from Boehringer Ingelheim. DFP-J has received travel grants from Pfizer, Roemmers, and Roche. MG has received consulting fees from Roche and Illumina. CV has received consulting fees (advisory role) from Lilly, PharmaMar, Pfizer, Eisai, Bayer, Mundipharma, GlaxoSmithKline, and travel grants from PharmaMar, Lilly, Novartis, Bayer, and Pfizer. CS has received research funding (institution) from Karyopharm, Pfizer, Inc, Deciphera Pharmaceuticals, and Bayer AG; consulting fees (advisory role) from CogentBio, Immunicum AB, Deciphera Pharmaceuticals and Blueprint Medicines; payment for lectures from Bayer AG and Blueprint Medicines; and travel grants from PharmaMar, Pfizer, Bayer AG, Novartis, and Lilly. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}